Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.
A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.
A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.
A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to findings presented at the European Society of Cardiology (ES...
A large analysis presented at the ASMBS Annual Meeting found bariatric surgery led to greater long-term weight loss than GLP-1 medications semaglutide and tirzepatide over three years.